German pharmaceutical firm Schering's diagnostics and radiopharmaceuticals business unit reported 2002 net sales of $1.52 billion (U.S.), down 3% compared with the $1.57 billion booked in 2001.
The Berlin-based vendor's MRI segment sales climbed 2%, however, despite an adverse exchange rate effect of 6%. The MRI gains were due mainly to a slight rise in net sales of its Magnevist agent, as well as growth of its Gadovist agent, Schering said.
Net sales of application technologies grew 9% in 2002 (up 16% after currency adjustments) from $260.9 million to $284.7 million, while x-ray contrast media sales dipped 9% from $778.6 million to $705.2 million. The decline in x-ray business was largely due to negative price and exchange rate effects, especially in Japan, Schering said. Sales volumes remained essentially stable.
Schering's radiopharmaceutical unit generated net sales of $157.4 million in 2002, down 4% from 2001. In 2003, Schering said it would focus on consolidating its market position for MRI contrast agents.
By AuntMinnie.com staff writersFebruary 28, 2003
Related Reading
Peregrine, Schering team up, January 7, 2003
Schering gets Japanese approval for Resovist, October 10, 2002
Schering sales, earnings climb, February 5, 2002
Schering buys rest of CIS bio, January 3, 2002
Copyright © 2003 AuntMinnie.com
